Sphere Bio joins MabDesign: accelerating biotherapeutic innovation together
As the newest international member of MabDesign, we’re expanding our reach across Europe and supporting the future of biologics development.
Cambridge, UK [20 March, 2025]: We’re proud to announce that Sphere Bio has joined MabDesign, the leading French network supporting innovation in biotherapies and biomanufacturing.
As a pioneer in picodroplet microfluidics, our mission is to help scientists around the world find, select, and scale the rare cells that lead to life-changing therapies. From antibody discovery to cell therapy and cell line development, our Cyto-Mine® platform empowers researchers to screen millions of single cells with speed, precision, and monoclonality assurance—helping ideas reach the clinic faster.
Joining MabDesign allows us to connect with more biopharma innovators across France and beyond, building deeper relationships in one of the most vibrant and growing hubs for biotherapeutics in Europe.
“We’re thrilled to become a part of MabDesign’s trusted network. France has always been a dynamic region for science and innovation, and this partnership will help us support even more researchers looking to advance biologics discovery and development.”
— Hafid Kora, Regional Account Manager France, Sphere Bio
Together with the MabDesign community, we’re championing bold ideas and smarter science. If you’re attending an upcoming MabDesign event—or just curious about what’s possible with single-cell microfluidics—we’d love to connect.
Let’s accelerate the future of biologics, together.
Learn more about MabDesgin: https://mabdesign.fr
About Fluidic Sciences and Sphere Bio
Fluidic Sciences develops transformative in‑solution technologies for protein interaction analysis. Its flagship Fluidity One‑M instrument leverages Microfluidic Diffusional Sizing (MDS) to measure binding affinity, stoichiometry, size, and concentration without immobilization—directly in complex backgrounds such as serum, plasma, and lysate.
Sphere Bio technology develops and manufactures single‑cell analysis and monoclonality assurance systems that enable researchers to find, analyze, and isolate the most valuable cells with speed and precision. Its proprietary picodroplet microfluidics and Cyto‑Mine® Chroma multiplexing platform power applications across antibody discovery, cell line development, cell engineering, and cell therapy.
For more information contact:
